Pertuzumab (Perjeta) for HER2-Positive Metastatic Breast Cancer
Pertuzumab (Perjeta – Roche/Genentech), a humanized
monoclonal antibody, has been approved by the FDA for
use in combination with trastuzumab (Herceptin) and
docetaxel (Taxotere, and others) for first-line treatment of
human epidermal growth factor receptor 2 (HER2)-positive
metastatic breast cancer....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: Pertuzumab (Perjeta) for HER2-Positive Metastatic Breast Cancer
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1395
Article Code: 1395c
Date: July 23, 2012
Volume: 54
Pages: 59-60
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1395
Article Code: 1395c
Date: July 23, 2012
Volume: 54
Pages: 59-60
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article. Add this downloadable, electronic article to your cart (U.S. English version only)
